Arabic Arabic English English French French German German
dark

Departure of Founder and CEO Heightens Uncertainty for Galapagos

As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Medtech Incubators and Accelerators: Where Are the Hubs for Medical Device Innovation?

Next Post

Organ transplants fell by a third worldwide during first wave of COVID-19 pandemic, new study presented at ESOT Congress 2021 shows

Related Posts
Total
0
Share